CA2630553A1 - Estrogen cancer therapy - Google Patents

Estrogen cancer therapy Download PDF

Info

Publication number
CA2630553A1
CA2630553A1 CA002630553A CA2630553A CA2630553A1 CA 2630553 A1 CA2630553 A1 CA 2630553A1 CA 002630553 A CA002630553 A CA 002630553A CA 2630553 A CA2630553 A CA 2630553A CA 2630553 A1 CA2630553 A1 CA 2630553A1
Authority
CA
Canada
Prior art keywords
cancer
estrogen
patient
paclitaxel
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002630553A
Other languages
English (en)
French (fr)
Inventor
Jack Singer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTI Biopharma Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37891993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2630553(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2630553A1 publication Critical patent/CA2630553A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002630553A 2005-12-06 2006-12-05 Estrogen cancer therapy Abandoned CA2630553A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74272505P 2005-12-06 2005-12-06
US60/742,725 2005-12-06
US81422106P 2006-06-16 2006-06-16
US60/814,221 2006-06-16
PCT/US2006/046281 WO2007067498A1 (en) 2005-12-06 2006-12-05 Estrogen cancer therapy

Publications (1)

Publication Number Publication Date
CA2630553A1 true CA2630553A1 (en) 2007-06-14

Family

ID=37891993

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002630553A Abandoned CA2630553A1 (en) 2005-12-06 2006-12-05 Estrogen cancer therapy

Country Status (9)

Country Link
US (1) US20070167349A1 (enExample)
EP (1) EP1957065A1 (enExample)
JP (1) JP2009518406A (enExample)
KR (1) KR20080074202A (enExample)
CA (1) CA2630553A1 (enExample)
PE (1) PE20070701A1 (enExample)
RU (1) RU2008127309A (enExample)
TW (1) TWI322010B (enExample)
WO (1) WO2007067498A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014250A1 (en) * 2008-08-01 2010-02-04 Cell Therapeutics, Inc. Prediction of cancer therapy based on cathespin b levels
WO2010014249A1 (en) * 2008-08-01 2010-02-04 Cell Therapeutics, Inc. Cancer therapy comprising estrogen inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
GB9120653D0 (en) * 1991-09-27 1991-11-06 Procter & Gamble Dispensing agent
US5731316A (en) * 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5977163A (en) * 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
CA2366697A1 (en) * 1999-02-26 2000-08-31 Larry Helson Treatment regimen for hormone-sensitive cancers
JP2003511423A (ja) * 1999-10-12 2003-03-25 セル・セラピューティックス・インコーポレーテッド ポリグルタメート−治療薬コンジュゲートの製造

Also Published As

Publication number Publication date
TWI322010B (en) 2010-03-21
TW200803836A (en) 2008-01-16
PE20070701A1 (es) 2007-07-20
WO2007067498A1 (en) 2007-06-14
RU2008127309A (ru) 2010-01-20
KR20080074202A (ko) 2008-08-12
JP2009518406A (ja) 2009-05-07
US20070167349A1 (en) 2007-07-19
EP1957065A1 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
US20230372499A1 (en) Dendrimer compositions and methods for drug delivery
Luo et al. IL-12 nanochaperone-engineered CAR T cell for robust tumor-immunotherapy
CN103002919B (zh) 纳米聚合物对免疫调节剂的肿瘤靶向递送
AU2018368520B2 (en) Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of Cathepsin B
US20180360978A1 (en) Polyacetal polymers, conjugates, particles and uses thereof
CN102083468A (zh) 用于治疗癌症的聚合物紫杉醇结合物和方法
KR20140050628A (ko) 단백질-중합체-약물 접합체
US20250049963A1 (en) Glycosylated dendrimers for targeted intracellular delivery
JP2023548310A (ja) Ｆａｐ活性化血清半減期延長型治療用コンジュゲート
Xiao et al. Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma
US20230381183A1 (en) USE OF FOLIC ACID AND FOLATE MODIFICATION IN INDUCING B-CELL IMMUNE TOLERANCE AND TARGETING mIgM-POSITIVELY-EXPRESSED B-CELL LYMPHOMA
US20070167349A1 (en) Estrogen cancer therapy
WO2019079767A1 (en) IMMUNOTHERAPEUTIC AGENTS TARGETING MACROPHAGES
WO2003017938A2 (en) Conjugates targeted to target receptors
Gritli et al. Polymeric nanoparticles and cancer: Lessons learnt from CRLX101
MX2008007281A (en) Estrogen cancer therapy
WO2010014249A1 (en) Cancer therapy comprising estrogen inhibitors
US20250121091A1 (en) Particles with covalently lipid-bound immunostimulatory agents
Mendelsohn et al. Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
WO2025166213A1 (en) Treatment of head and neck cancer with pharmaceutical composition comprising nanoparticles containing taxane
US20250049936A1 (en) Bioorthogonal compositions
WO2010014250A1 (en) Prediction of cancer therapy based on cathespin b levels
Nguyen Chemical modification of drugs to promote their self-assembly into nanoparticles for improved delivery
WO2025080269A1 (en) Particles with covalently lipid-bound immunostimulatory agents
HK40081468A (en) Dendrimer compositions and methods for drug delivery

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued